(Q36583826)

15 August 2017

0 references

1 reference

title

Meta-analysis: terlipressin therapy for the hepatorenal syndrome (English)

1 reference

15 August 2017

1 reference

Fabrizi F

1

1 reference

15 August 2017

Dixit V

series ordinal

2

1 reference

15 August 2017

Martin P

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Alimentary Pharmacology & Therapeutics

15 August 2017

number of pages

10

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

15 August 2017

volume

24

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

935-944

1 reference

Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Hepatorenal syndrome: combined liver kidney transplants versus isolated liver transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

The retrieval of randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Approaches to heterogeneity in meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Renal failure in cirrhotic patients: role of terlipressin in clinical approach to hepatorenal syndrome type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

A model to predict survival in patients with end-stage liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2006.03086.X

10.1111/J.1365-2036.2006.03086.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference